Application of BRET Technology to Quantitatively Determine Kinase Inhibitor Potency in

Tuesday, November 6, 2018

Methods for measuring kinase inhibitor potency in live cells are limited. In this webinar, we describe how the NanoBRET™ Target Engagement technique is overcoming technical limitations of existing methods by broadly enabling quantitative determination of kinase inhibitor occupancy in live cells. We also discuss a collaboration between Promega and Reaction Biology Corporation that has enabled conversion of these assays into a service compatible with high-throughput cell-based profiling.

View Webinar Recording 

 Matthew Robers  

Matthew Robers is a Senior Research Scientist and Group Leader at Promega Corporation. 

Matthew has authored 30 peer-reviewed publications and published patents on the application

of novel assay chemistries to measure intracellular protein dynamics. Matthew's team currently focuses on the development of new technologies to assess target engagement, emphasizing techniques enabling quantitative analysis of compound affinity and residence time at selected targets within intact cells.

 Kelvin Lam  

Kelvin Lam is the Senior Director of Business Development at Reaction Biology Corporation. He is also the Founder and President of Simplex Pharma Advisors, Inc., which offers consulting services to early drug discovery companies. Since 2003, he has been one of the Editors-in-Chief of Drug Discovery Today, Technologies (Elsevier). Previously he held leadership and scientist positions at Blue Sky Biosciences, Harvard Stem Cell Institute, Pfizer, Inc. and ScriptGen Pharmaceuticals. Kelvin holds a Ph.D. in Biochemistry from Boston University School of Medicine and a B.A. in Chemistry from University of Hawaii at Manoa. He completed his postdoctoral-training at Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center.